-
Mashup Score: 0Retrospective Data Show BTK Inhibitors May Be Optimal Second-Line Approach in Late-Relapse Mantle Cell Lymphoma - 4 hour(s) ago
Second-line BTK inhibitors were associated with improved PFS2 and OS2 in late-relapsed mantle cell lymphoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1Bendamustine/Obinutuzumab Induction Generates Favorable Responses and MRD Negativity in Treatment-Naive MCL - 5 hour(s) ago
Induction therapy with bendamustine plus obinutuzumab resulted in higher CR rates compared with historical rates of CR with BR in treatment-naive MCL.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Bendamustine/Obinutuzumab Induction Generates Favorable Responses and MRD Negativity in Treatment-Naive MCL #lymsm #oncology https://t.co/T307vxGtFA
-
-
Mashup Score: 0Retrospective Data Show BTK Inhibitors May Be Optimal Second-Line Approach in Late-Relapse Mantle Cell Lymphoma - 5 day(s) ago
Second-line BTK inhibitors were associated with improved PFS2 and OS2 in late-relapsed mantle cell lymphoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Retrospective Data Show BTK Inhibitors May Be Optimal Second-Line Approach in Late-Relapse Mantle Cell Lymphoma #lymsm #oncology https://t.co/k6d41483jU
-
-
Mashup Score: 1Bendamustine/Obinutuzumab Induction Generates Favorable Responses and MRD Negativity in Treatment-Naive MCL - 5 day(s) ago
Induction therapy with bendamustine plus obinutuzumab resulted in higher CR rates compared with historical rates of CR with BR in treatment-naive MCL.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Bendamustine/Obinutuzumab Induction Generates Favorable Responses and MRD Negativity in Treatment-Naive MCL #lymsm #oncology https://t.co/T307vxGtFA
-
-
Mashup Score: 0Indirect Comparison Shows Comparable Efficacy, Improved Safety for Acalabrutinib vs Ibrutinib in R/R Mantle Cell Lymphomal Lymphoma - 7 day(s) ago
An indirect comparison did not show significant differences in survival for acalabrutinib vs ibrutinib in relapsed/refractory mantle cell lymphoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Data from a matching-adjusted indirect comparison demonstrated that there was not a statistically significant difference in PFS or OS for acalabrutinib vs ibrutinib in patients with relapsed/refractory MCL @michaelwangmd @MDAndersonNews #lymsm #oncology https://t.co/5nYbhN1NNV https://t.co/Tyk3ZeeMdt
-
-
Mashup Score: 0Bispecific Antibodies, Novel Combinations Highlight Continued Treatment Evolution in Follicular Lymphoma - 19 day(s) ago
David C. Fisher, MD, discusses the evolving therapeutic landscape in follicular lymphoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
David C. Fisher, MD, spotlighted recent data in follicular lymphoma, including findings with the EZH2 inhibitor tazemetostat used in combination therapy, and data for the bispecific antibody epcoritamab. @DanaFarberNews #lymsm #oncology https://t.co/QMIaCI1OL9 https://t.co/d2Vc4vPmhV
-
-
Mashup Score: 1Nivolumab Plus AVD Prolongs PFS vs Brentuximab Vedotin Plus AVD in Advanced-Stage Hodgkin Lymphoma - 19 day(s) ago
Nivolumab plus AVD prolonged median PFS vs brentuximab vedotin plus AVD in patients with stage III or IV advanced-stage classic Hodgkin lymphoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Nivolumab plus AVD prolonged median PFS vs brentuximab vedotin plus AVD in patients with stage III or IV advanced-stage classic Hodgkin lymphoma. #lymsm #oncology https://t.co/CW1G9MCEiY
-
-
Mashup Score: 1Nivolumab Plus AVD Prolongs PFS vs Brentuximab Vedotin Plus AVD in Advanced-Stage Hodgkin Lymphoma - 21 day(s) ago
Nivolumab plus AVD prolonged median PFS vs brentuximab vedotin plus AVD in patients with stage III or IV advanced-stage classic Hodgkin lymphoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Nivolumab plus AVD prolonged median PFS vs brentuximab vedotin plus AVD in patients with stage III or IV advanced-stage classic Hodgkin lymphoma. #lymsm #oncology https://t.co/CW1G9MCEiY
-
-
Mashup Score: 2Meta-Analysis Shows Efficacy, Safety of CAR T-Cell Therapy in R/R Mantle Cell Lymphoma - 28 day(s) ago
CAR T-cell therapy demonstrated efficacy and manageable safety in mantle cell lymphoma in a systematic review of prospective and real-world studies.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Meta-Analysis Shows Efficacy, Safety of CAR T-Cell Therapy in R/R Mantle Cell Lymphoma @FrontImmunol #lymsm #oncology https://t.co/xeDRFowc6u
-
-
Mashup Score: 2Meta-Analysis Shows Efficacy, Safety of CAR T-Cell Therapy in R/R Mantle Cell Lymphoma - 1 month(s) ago
CAR T-cell therapy demonstrated efficacy and manageable safety in mantle cell lymphoma in a systematic review of prospective and real-world studies.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Meta-Analysis Shows Efficacy, Safety of CAR T-Cell Therapy in R/R Mantle Cell Lymphoma @FrontImmunol #lymsm #oncology https://t.co/xeDRFowc6u
-
Retrospective Data Show BTK Inhibitors May Be Optimal Second-Line Approach in Late-Relapse Mantle Cell Lymphoma #lymsm #oncology https://t.co/k6d41483jU